Annabel Romero, PhD
Annabel Romero, Ph.D., is the director of drug discovery and molecular modeling at SFL Scientific, leading the design and implementation of custom AI solutions for healthcare and life sciences clients. From target identification to FDA filing of novel drug patents, Annabel understands the current need to streamline and accelerate the process of finding candidate molecules in this complex domain, and serves as an expert in the field with over 10 years of focused research. At SFL, Annabel connects the needs of industry clients with novel AI and machine learning methodologies to radically transform the current state of their internal R&D processes.
Prior to joining SFL Scientific, Dr. Romero worked in the pharmaceutical industry and was a fundamental part of developing a monoclonal antibody cocktail against SARS-CoV-2, the virus for the COVID-19 disease. She has solved several structures of proteins relevant for disease treatment within small molecules and monoclonal antibodies. With a background in structural biology, biochemistry, genetics, and neuroscience, Dr. Romero is passionate about life’s essential motto, “structure reveals function,” and brings together protein structure and the various ‘omics’ data through AI in order to augment the current understanding of disease characterization.
Dr. Romero earned her BS in Biochemical Engineering from the National Polytechnic Institute in Mexico City, her MS in Genetics and Molecular Biology from the Center for Research and Advanced Studies in Mexico City, and a P.hD. in Biological Sciences from Cold Spring Harbor Laboratory in New York.